Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vancomycin | 8 | 2023 | 88 | 2.530 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 7 | 2023 | 88 | 1.630 |
Why?
|
| Anti-Bacterial Agents | 12 | 2023 | 820 | 1.450 |
Why?
|
| Staphylococcal Infections | 7 | 2023 | 300 | 1.200 |
Why?
|
| Area Under Curve | 5 | 2021 | 205 | 0.430 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2021 | 290 | 0.390 |
Why?
|
| Pediatrics | 2 | 2013 | 323 | 0.310 |
Why?
|
| Triazoles | 2 | 2005 | 120 | 0.280 |
Why?
|
| Malaria | 1 | 2006 | 37 | 0.280 |
Why?
|
| Pyrimidines | 2 | 2005 | 196 | 0.270 |
Why?
|
| Drug Monitoring | 3 | 2020 | 85 | 0.250 |
Why?
|
| Referral and Consultation | 1 | 2006 | 307 | 0.240 |
Why?
|
| Antifungal Agents | 2 | 2005 | 363 | 0.240 |
Why?
|
| Trichosporon | 1 | 2003 | 14 | 0.240 |
Why?
|
| Famotidine | 1 | 2003 | 11 | 0.230 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 23 | 0.220 |
Why?
|
| Mycoses | 1 | 2003 | 162 | 0.220 |
Why?
|
| Bacteremia | 1 | 2023 | 101 | 0.210 |
Why?
|
| Child | 10 | 2023 | 7341 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 492 | 0.200 |
Why?
|
| Consensus | 1 | 2021 | 157 | 0.190 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 231 | 0.190 |
Why?
|
| Humans | 18 | 2023 | 54284 | 0.190 |
Why?
|
| Cystic Fibrosis | 1 | 2022 | 157 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2020 | 58 | 0.180 |
Why?
|
| Respiratory System | 1 | 2015 | 28 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 84 | 0.130 |
Why?
|
| Tracheostomy | 1 | 2015 | 81 | 0.130 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 26 | 0.120 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 20 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 81 | 0.110 |
Why?
|
| United States | 6 | 2020 | 5217 | 0.110 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 272 | 0.110 |
Why?
|
| Infant | 5 | 2015 | 3817 | 0.100 |
Why?
|
| Pharmacists | 2 | 2020 | 152 | 0.080 |
Why?
|
| Plasmodium | 1 | 2006 | 4 | 0.070 |
Why?
|
| Specialization | 1 | 2006 | 46 | 0.070 |
Why?
|
| Antimalarials | 1 | 2006 | 30 | 0.070 |
Why?
|
| Geography | 1 | 2006 | 81 | 0.070 |
Why?
|
| Medicine | 1 | 2006 | 58 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2015 | 4147 | 0.060 |
Why?
|
| Azithromycin | 1 | 2005 | 42 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2005 | 122 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 40 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2004 | 41 | 0.060 |
Why?
|
| Candidiasis | 1 | 2005 | 122 | 0.060 |
Why?
|
| HIV-1 | 1 | 2004 | 72 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2003 | 225 | 0.060 |
Why?
|
| Neutropenia | 1 | 2003 | 120 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2003 | 178 | 0.050 |
Why?
|
| Methicillin | 1 | 2020 | 9 | 0.050 |
Why?
|
| Societies, Pharmaceutical | 1 | 2020 | 13 | 0.050 |
Why?
|
| HIV Infections | 1 | 2004 | 394 | 0.050 |
Why?
|
| Adolescent | 3 | 2015 | 6897 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2023 | 361 | 0.040 |
Why?
|
| Aging | 1 | 2005 | 784 | 0.040 |
Why?
|
| Lung | 1 | 2022 | 507 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 194 | 0.040 |
Why?
|
| Adult | 1 | 2015 | 14207 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 674 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2015 | 54 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 86 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 403 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 231 | 0.030 |
Why?
|
| Feedback | 1 | 2014 | 59 | 0.030 |
Why?
|
| Government Regulation | 1 | 2013 | 15 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2015 | 2907 | 0.030 |
Why?
|
| Infection Control | 1 | 2013 | 57 | 0.030 |
Why?
|
| Patient Safety | 1 | 2013 | 121 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 321 | 0.030 |
Why?
|
| Program Development | 1 | 2013 | 199 | 0.030 |
Why?
|
| Health Policy | 1 | 2013 | 171 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2013 | 374 | 0.030 |
Why?
|
| Animals | 1 | 2006 | 14385 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1025 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 397 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2015 | 6432 | 0.020 |
Why?
|
| Directly Observed Therapy | 1 | 2004 | 8 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 8 | 0.020 |
Why?
|
| Foster Home Care | 1 | 2004 | 17 | 0.020 |
Why?
|
| Viral Load | 1 | 2004 | 85 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2004 | 139 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2004 | 141 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 313 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 377 | 0.010 |
Why?
|
| Home Care Services | 1 | 2004 | 79 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2005 | 335 | 0.010 |
Why?
|
| Child Abuse | 1 | 2004 | 170 | 0.010 |
Why?
|
| Male | 2 | 2015 | 27334 | 0.010 |
Why?
|
| Female | 2 | 2015 | 28441 | 0.010 |
Why?
|